期刊文献+

新型结核病疫苗AEH/Al/IC在小鼠中的免疫原性研究 被引量:1

Immunogenicity of a new TB vaccines AEH with aluminum hydroxide and poly(I:C) in mice
下载PDF
导出
摘要 目的检测重组结核分枝杆菌(Mycobacterium tuberculosis,Mtb)融合蛋白Ag85B-ESAT6(Antigen 85 B,6-kDa early secretory antigenic target,AE)和热休克蛋白X(heat shock protein X,HspX)与氢氧化铝和聚肌胞苷酸(Polyinosinic-polycytidylic acid,poly I∶C)构建的新型结核病亚单位疫苗AEH/Al/IC在小鼠中的免疫原性。方法用疫苗(AEH/Al/IC)和佐剂(Al/Poly I∶C)分别免疫雌性BALB/c小鼠3剂次,每剂次间隔10 d。末次免疫后第10天,经ELISA检测小鼠血清中抗原特异性IgG、IgG1和IgG2a的抗体效价,经酶联免疫斑点试验(enzyme-linked immunospot,ELISPOT)检测小鼠脾细胞分泌抗原特异性IFN-γ和IL-2的细胞频数,经ELISA检测小鼠脾细胞抗原特异性IFN-γ、IL-2和TNF-α的分泌量。结果与佐剂组相比,疫苗组诱导小鼠产生了高水平的AE和HspX特异性抗体;疫苗组诱导小鼠产生的AE和HspX特异性IFN-γ和IL-2阳性脾淋巴细胞(斑点形成细胞spot forming cells,SFC)均高于佐剂组,差异有统计学意义(IFN-γ:P<0.05;IL-2:P<0.05);疫苗组小鼠脾细胞AE特异性IFN-γ、IL-2和TNF-α分泌量明显较佐剂组高,差异均有统计学意义(P<0.05),HspX特异性IFN-γ和TNF-α分泌量比佐剂组稍高,但差异均无统计学意义(P>0.05)。结论结核病亚单位疫苗AEH/Al/IC具有良好的免疫原性,有希望成为一种新型的结核病预防候选疫苗。 Objective To evaluate the immunogenicity of a novel subunit vaccine AEH,which is comprised of recombinant Mycobacterium tuberculosis fusion protein Ag85B-ESAT6(Antigen 85 B,6-kDa early secretory antigenic target,AE)and HspX(heat shock protein X),in conjunction with aluminum hydroxide(Al)and poly I∶C in mice.Methods Female BALB/c mice were immunized with the vaccine(AEH/Al/IC)or Al/poly I∶C for 3 doses 3 days apart.Serum samples were collected 10 d after the last injection and determined for IgG/IgG1/IgG2a titer by indirect ELISA,the number of spleen cells secreted IFN-γand IL-2 was detected by ELISPOT,the level of IFN-γ,IL-2 and TNF-αin spleen cells was detected by ELISA.Results The detection of antibody showed that the levels of anti-AE and anti-HspX IgG,IgG1 and IgG2a in vaccine group were higher than the adjuvant group.ELISPOT assay showed that the AE and HspX-specific IFN-γand IL-2 spot forming cells(SFC)produced by the spleen lymphocytes of the vaccine group were significant higher than the adjuvant group(IFN-γ:P<0.05,IL-2:P<0.05).The results of cytokine ELISA showed that the levels of AE-specific IFN-γ,IL-2 and TNF-αproduced by spleen cells of the vaccine group were significantly higher than the adjuvant group(P<0.05);HspX-specific IFN-γand TNF-αproduced by spleen cells of the vaccine group were slightly higher than the adjuvant group,but the difference was not statistically significant(P>0.05).Conclusion The data indicated that the AEH/Al/IC was highly immunogenic in mice,it may represent a promising candidate vaccine for the control of TB.
作者 杨蕾 王春花 卢锦标 都伟欣 沈小兵 苏城 王国治 YANG Lei;WANG Chun-hua;LU Jin-biao;DU Wei-xin;SHEN Xiao-bin;SU Cheng;WANG Guo-zhi(Division of Tuberculosis Vaccines,National Institutes for Food and Drug Control,Beijing 102629,China)
出处 《微生物学免疫学进展》 2019年第6期28-33,共6页 Progress In Microbiology and Immunology
基金 中检院“中青年发展研究基金”(2016B3)
关键词 结核病疫苗 佐剂 免疫原性 Tuberculosis vaccine Adjuvant Immunogenicity
  • 相关文献

参考文献5

二级参考文献90

  • 1赵爱华,贾淑珍,乔来艳,寇丽杰,王国治.BCG-CpG-DNA制备、理化特性及免疫刺激活性的初步研究[J].微生物学免疫学进展,2005,33(1):39-43. 被引量:18
  • 2Kaufmann SH. Future vaccination strategies against tuberculosis., thinking outside the box [J]. Immunity, 2010, 33(4) : 567-577.
  • 3Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, Andersen P. A multistage tuberculosis vaccine that confers efficient protection before and after exposure [J]. Nat Med, 2011, 17(2): 189-194.
  • 4Lin MY, Ottenhoff TH. Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection [J]. Biol Chem, 2008, 389(5) : 497-511.
  • 5Ahmad Z, Sharma S, Khuller GK. The potential of azolc antifungals against latent/persistent tuberculosis [J]. FEMS Microbiol Lett, 2006, 258(2): 200-203.
  • 6Hamborg M, Kramer R, Schant6 CE, Agger EM, Christensen D, Jorgensen L, Foged C, Middaugh CR. The physical stability of the recombinant tuberculosis fusion antigens hl and h56 [J]. J Pharm Sci, 2013, 102(10): 3567-3578.
  • 7Lin PL, Dietrich J, Tan E, Abalos RM, Burgos J, Bigbce C, Bigbee M, Milk L, Gideon HP, Rodgers M, Cochran C, Guinn KM, Sherman DR, Klein E, Janssen C, Flynn JL, Andersen P. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection [J]. J Clin Invest, 2012, 122(1 ): 303- 314.
  • 8Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M, Phan T, Orme IM, Vedvick TS, Baldwin SL, Coler RN, Reed SG. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug- resistant Mycobacterium tuberculosis [J]. Sci Transl Med, 2010, 2(53): 53ra74.
  • 9Vilaplana C, Gil O, Cficeres N, Pinto S, Diaz J, Cardona PJ. Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis [J]. PLoS One, 2011, 6(5): e20404.
  • 10Vilaplana C, Montan6 E, Pinto S, Barriocanal AM, Domenech G, Torres F, Cardona PJ, Costa J. Double- blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI [J]. Vaccine, 2010, 28(4): 1106-1116.

共引文献14

同被引文献2

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部